References of "Cavalier, Etienne"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPerformance characteristics of the VIDAS 25-OH Vitamin D total assay - comparison with four immunoassays and two liquid chromatography-tandem mass spectrometry methods in a multicentric study
Moreau, E; Bächer, S; Mery, S et al

in Clinical Chemistry & Laboratory Medicine (in press)

Background: The study was conducted to evaluate the analytical and clinical performance of the VIDAS® 25-OH Vitamin D Total assay. The clinical performance of the assay was compared with four other ... [more ▼]

Background: The study was conducted to evaluate the analytical and clinical performance of the VIDAS® 25-OH Vitamin D Total assay. The clinical performance of the assay was compared with four other immunoassays against the results of two different liquid chromatography/ mass spectrometry methods (LC-MS/MS) standardized to NIST reference materials. Methods: VIDAS® 25-OH Vitamin D Total assay precision, linearity, detection limits and sample matrix comparison were assessed following CLSI guidelines. For method comparison, a total of 150 serum samples ranging from 7 to 92 ng/mL were analyzed by all the methods. Correlation was studied using Passing-Bablok regression and Bland- Altman analysis. The concordance correlation coefficient (CCC) was calculated to evaluate agreement between immunoassays and the reference LC-MS/MS method. In addition, samples containing endogenous 25(OH)D2 were used to assess each immunoassay’s ability to detect this analyte. Pregnancy and hemodialysis samples were used to the study the effect of vitamin D binding protein (DBP) concentration over VIDAS® assay performance. Results: The VIDAS® 25-OH Vitamin D Total assay showed excellent correlation to the LC-MS/MS results (y = 1.01x+0.22 ng/mL, r = 0.93), as obtained from two different sites and distinct LC-MS/MS methods. The limit of quantification was determined at 8.1 ng/mL. Cross-reactivity for 25(OH)D2 was over 80%. At concentrations of 10.5, 26 and 65.1 ng/mL, within-run CVs were 7.9%, 3.6% and 1.7%, while total CVs (between runs, calibrations, lots and instruments) were 16.0%, 4.5% and 2.8%. The VIDAS® performance was not influenced by altered DBP levels, though under-recovery of 25(OH)D as compared to LC-MS/ MS was observed for hemodialysis samples. Conclusions: The VIDAS® 25-OH Vitamin D Total assay is therefore considered suitable for assessment of vitamin D status in clinical routine. Keywords: assay performance; liquid chromatography/ [less ▲]

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailAdaptation posologique des médicaments et fonction rénale : Quel(s) estimateur(s) faut-il choisir?
DELANAYE, Pierre ULg; Flamant, M; CAVALIER, Etienne ULg et al

in Néphrologie & Thérapeutique (in press)

Le choix de la formule d’estimation du de´ bit de filtration glomérulaire (DFG) a` utiliser pour l’adaptation posologique fait encore de´ bat, principalement entre la formule de Cockcroft et les équations ... [more ▼]

Le choix de la formule d’estimation du de´ bit de filtration glomérulaire (DFG) a` utiliser pour l’adaptation posologique fait encore de´ bat, principalement entre la formule de Cockcroft et les équations plus récentes, MDRD (pour Modified Diet in Renal Disease) et CKD-EPI (pour Chronic Kidney Disease Epidemiology). Les arguments mis en avant en faveur de l’utilisation de la formule de Cockcroft sont : qu’elle a été préférentiellement utilisée pour décider des adaptations posologiques avant la mise sur le marché des médicaments, qu’elle permettrait une meilleure prédiction du risque de survenue des effets indésirables a` l’accumulation des médicaments, qu’elle permettrait de limiter le surdosage médicamenteux chez la personne âgée. Dans cet article d’opinion, nous discutons les faiblesses de l’argumentaire des partisans du maintien de l’utilisation de la formule de Cockcroft dans le contexte de l’adaptation posologique, ainsi que les limites et le manque de fiabilité de cette formule. Nous soutenons la recommandation de la Haute Autorité de sante´ (HAS) sur l’utilisation systématique, en 2015, de l’équation CKD-EPI pour l’estimation du DFG. Lorsque le DFG est e´ value´ dans le but d’adapter la posologie d’un médicament, la désindexation de la surface corporelle est préférable. Compte tenu des difficultés d’estimation du DFG chez la personne âgée et chez les individus a` gabarit hors norme, nous recommandons d’utiliser en priorité dans ces populations, des médicaments pour lesquels un suivi pharmacologique est disponible, ou d’avoir recours à une méthode de référence de mesure du DFG. [less ▲]

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailMeasurement of circulating 25-hydroxyvitamin D: A historical review
Delvin, Edgar; LE GOFF, Caroline ULg; CAVALIER, Etienne ULg et al

in Practical Laboratory Medicine (in press)

The constantly increasing requests for the measurement of serum 25-hydroxyvitamin D over the last years has led reagent manufacturers to market different automated and semi-automated methods, that being ... [more ▼]

The constantly increasing requests for the measurement of serum 25-hydroxyvitamin D over the last years has led reagent manufacturers to market different automated and semi-automated methods, that being unfortunately not fully harmonized, yield different results. Liquid chromatography coupled to tandem mass spectrometry (LC/MS2) has more recently been introduced. This approach allows the distinction between the two forms of 25-hydroxyvitamin D and to measure other metabolites. This approach also requires harmonization to curtail the differences between the different analytical methods. To meet this requirement, the American National Institutes of Health (NIH), the CDC (Centre for Disease Control and Prevention) in Atlanta, the NIST (National Institute of Standards and Technology) and the vitamin D Reference laboratory of Ghent University have pooled their expertise to develop a standardization program. This article reviews the main elements and the difficulties of the automated and semi-automated methods for 25-hydroxyvitamin D, from sample preparation to the analytical phase, as well as those related to mass spectrometry. It also addresses the issues related to the clinical decision thresholds and the possibility of measurements in different biological liquids. [less ▲]

Detailed reference viewed: 28 (1 ULg)
Full Text
See detailPersistent low levels of serum hCG due to heterophilic mouse antibodies: an unrecognized pitfall in the diagnosis of trophoblastic disease.
Gonzalez Aguilera, B.; Syrios, P.; Gadisseur, R et al

in Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2016)

Phantom hCG refers to persistent mild elevations of hCG, leading physicians to unnecessary treatments whereas neither a true hCG nor a trophoblastic disease is present. We report the case of a 23-year-old ... [more ▼]

Phantom hCG refers to persistent mild elevations of hCG, leading physicians to unnecessary treatments whereas neither a true hCG nor a trophoblastic disease is present. We report the case of a 23-year-old woman with persistent low levels of serum hCG detected one month after miscarriage. As choriocarcinoma was suspected, a chemotherapy trial of methotrexate was prescribed, without any hCG reduction. Subsequently, laparoscopy ruled out a trophoblastic residue and the patient was referred to the Endocrine Unit for further investigations. While low levels of hCG were still detected in serum, no hCG was detected in the urine. In addition, when serum was processed in a HBT tube for revealing heterophilic antibodies, hCG was no longer detected. Such finding indicated the presence of phantom hCG due to heterophilic mouse antibodies interaction. This case raises the need of clinico-biological discussion to avoid inappropriate therapeutic decisions. Based on this case experience and after review of the literature, we suggest that current gynecological protocols for the diagnosis and treatment of trophoblastic disease should consider the inclusion of urinary hCG and/or a test for serum heterophilic antibodies when appropriate. [less ▲]

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailEfficiency of delivery observed treatment in hemodialysis patients: the example of the native vitamin D therapy
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Fafin, Coraline et al

in Journal of Nephrology (2016), 29(1), 99-103

Introduction Adherence to therapy is a relevant challenge in chronic hemodialysis patients. The directly observed therapy (DOT) could be an effective method to increase adherence for specific therapies ... [more ▼]

Introduction Adherence to therapy is a relevant challenge in chronic hemodialysis patients. The directly observed therapy (DOT) could be an effective method to increase adherence for specific therapies. We aimed to study the performance of DOT versus home medication. We follow the impact of providing native vitamin D directly by the nurse after a dialysis session on the 25-hydroxyvitamin [25(OH)D] concentrations. Methods In this observational study, we included 38 dialysis patients treated by stable dosage of cholecalciferol. DOT was implemented in December 2010. We considered the concentrations of 25-OH vitamin D three times before (T1 = June 2010, T2 = July 2010 and T3 = September 2010) and three times after the modification of prescription (T4 = February 2011, T5 = March 2011 and T6 = April 2011). Results Median age was 72 [62; 79] years and 48 % were diabetics. Mean body mass index was 26 ± 5 kg/m2 and median dialysis vintage was 20 [8; 46] months. The patients were compared to themselves. Before DOT, median concentrations of 25(OH)D were 27 (14–36), 23 (17–31), 31 (22–38) ng/mL at T1, T2 and T3, respectively. When DOT was effective, the concentrations significantly increased to 34 (28–44), 35 (29–41), 39 (32–47) ng/mL at T4, T5 and T6, respectively. Before DOT, 19 patients (50 %) reached the target of 30 ng/mL. After DOT, 29 patients (76 %) reached the target concentration of 30 ng/ mL. Conclusions In hemodialysis patients, DOT is both simple and effective to increase the therapeutic impact to native vitamin D. [less ▲]

Detailed reference viewed: 22 (7 ULg)
Full Text
Peer Reviewed
See detailSerum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations
Souberbielle, JC; CAVALIER, Etienne ULg; DELANAYE, Pierre ULg et al

in Clinica Chimica Acta (2015), 451 (Pt B)

The measurement of calcitriol [1,25(OH2)D], is important for the differential diagnosis of several disorders of calcium/phosphorus metabolism but is time-consuming and tricky. We measured serum calcitriol ... [more ▼]

The measurement of calcitriol [1,25(OH2)D], is important for the differential diagnosis of several disorders of calcium/phosphorus metabolism but is time-consuming and tricky. We measured serum calcitriol with a new automated direct assay on the Liaison XL platform in 888 healthy French Caucasian subjects aged 18–89 years, 32 patients with a surgically-proven PHPT, 32 pregnant women at the end of the first and at the end of the third trimester, and 24 dialysis patients before and after one year of supplementationwith vitamin D3 or placebo. The mean calcitriol concentration (±SD) in the healthy population was 52.9 ± 14.5 ng/L with a 95% CI interval of 29–83.6 ng/L. In PHPT patients, calcitriol concentration was 81.6±29.0 ng/L, 15 of them (46.9%) having a concentration N83.6 ng/L. In pregnant women, calcitriol was 80.4 ± 26.4 ng/L at the end of the first trimester, and 113.1±33.0 ng/L at the end of the third trimester, 12 (37.5%) and 26 (81.3%) of them having a calcitriol concentration N83.6 ng/L at the first and third trimesters respectively. In 14 dialysis patients, calcitriol was 9.5±7.7 ng/L and rose to 19.3 ng/L after one year of supplementation with 50,000 IU vitamin D3/month. In 10 other dialysis patients, calcitriol was 9.9±2.9 ng/L and remained stable (12.4±3.7 ng/L) after one year of placebo. In conclusion, this new automated calcitriol assay, in addition to presenting excellent analytical performances, gives the expected variations in patients compared to “normal” values obtained in an extensive reference population [less ▲]

Detailed reference viewed: 17 (3 ULg)
See detailKDIGO a guidelines for bone turnover management in dialysis patients
CAVALIER, Etienne ULg

Conference (2015, November 20)

Detailed reference viewed: 5 (0 ULg)
See detail3rd Generation PTH: Clinical utility
CAVALIER, Etienne ULg

Conference (2015, November 20)

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailLa prise en charge interdisciplinaire des patients lithiasiques réduit-elle à long terme le taux de geste urologique pour récidive ?
Castiglione, Vincent ULg; Pieroni, Laurence; Conort, Pierre et al

Poster (2015, October 01)

Certains patients lithiasiques sont hautement récidivants, malgré les progrès considérables en urologie et une prise en charge des facteurs de risque. Nous avons fait l’hypothèse qu’une prise en charge ... [more ▼]

Certains patients lithiasiques sont hautement récidivants, malgré les progrès considérables en urologie et une prise en charge des facteurs de risque. Nous avons fait l’hypothèse qu’une prise en charge interdisciplinaire au long court dédiée au diagnostic du processus lithogène, à l’analyse des causes de récidive, et à la détermination d'objectifs chiffrés de prévention, réduirait le nombre de gestes chirurgicaux pour récidive lithiasique et améliorerait ainsi la qualité de vie des patients. [less ▲]

Detailed reference viewed: 29 (8 ULg)
See detailPerformances analytiques d’un biomarqueur : dialogue
CAVALIER, Etienne ULg

Conference (2015, September 23)

Detailed reference viewed: 9 (1 ULg)
See detailAnalytical performance of a biomarker: what the clinician should know
CAVALIER, Etienne ULg

Conference (2015, September 17)

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailIdentification of cardiac repercussions after intense and prolonged concentric isokinetic exercise in young sedentary people
LE GOFF, Caroline ULg; Kaux, Jean-François ULg; Couffignal, Vincent et al

in Clinical physiology and functional imaging (2015), 35(5), 368-375

INTRODUCTION: Cardiopathies are the world's leading cause of mortality and morbidity. Although rare, cardiovascular accidents can occur during intense and infrequent sporting activity, particularly among ... [more ▼]

INTRODUCTION: Cardiopathies are the world's leading cause of mortality and morbidity. Although rare, cardiovascular accidents can occur during intense and infrequent sporting activity, particularly among those who are unaware of their heart condition. The development of cardiospecific biochemical markers has led to a reconsideration of the role of biology in the diagnosis of cardiovascular illnesses. The aim of this study therefore was, through the use of cardiac biomarker assays, to highlight the impact of sustained physical effort in the form of intense and prolonged concentric isokinetic exercise and to research potential cardiovascular risks. MATERIALS AND METHODS: Eighteen subjects participated in a maximal concentric isokinetic exercise involving 30 knee flexion-extensions for each leg. Five blood tests were taken to study the kinetics of the cardiac biomarkers. Haemodynamic parameters were measured continuously using a Portapres, and respiratory parameters were measured using a Sensormedics Vmax 29C. RESULTS: The results showed significant increases in the creatine kinase, myoglobin, homocysteine and haemoglobin cardiac markers. Evolutionary trends were also observed for the following biomarkers: NT-proBNP, myeloperoxydase and C-reactive protein. All the physiological parameters measured presented statistically significant changes. CONCLUSION: Isokinetic effort leads to the release of cardiac markers in the blood, but these do not exceed the reference values in healthy subjects. Maximal concentric isokinetic exercise does not, therefore, lead to an increased risk of cardiovascular pathologies. [less ▲]

Detailed reference viewed: 99 (41 ULg)
Full Text
Peer Reviewed
See detailVitamin D status after a high dose of cholecalciferol in healthy and burn subjects
ROUSSEAU, Anne-Françoise ULg; DAMAS, Pierre ULg; LEDOUX, Didier ULg et al

in Burns : Journal of the International Society for Burn Injuries (2015), 41(5), 1028-1034

Background: Burn patients are at risk of vitamin D (VD) deficiency and may benefit from its pleiotropic effects as soon as acute phase. Aim of this observational study was to assess effects of a ... [more ▼]

Background: Burn patients are at risk of vitamin D (VD) deficiency and may benefit from its pleiotropic effects as soon as acute phase. Aim of this observational study was to assess effects of a cholecalciferol (VD3) bolus on VD status in adult burn patients (Group B, GB) after admission, compared to healthy subjects (Group H, GH). Methods: Both groups received an oral dose of 100,000 IU VD3. Blood samples were collected before (D0) and 7 days (D7) after bolus to measure 250H-D, 1,25(OH)2-D, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23). Albumin (ALB) and VD binding protein (DBP) were measured and used to calculate free 25OH-D level. Data were expressed as median (min–max) or proportions. Results: A total of 49 subjects were included: 29 in GH and 20 in GB. At D0, prevalence of VD deficiency was higher in GB: 25OH-D was 21.5 (10.1–46.3) ng/ml in GH vs 11 (1.8–31.4) ng/ml in GB. DBP and ALB were lower in GB. At D7, DBP was stable in both groups while ALB decreased in GB. 25OH-D increased by 66.6 (13.5–260.3)% in GH. In GB, changes in 25OH-D extended from 36.7% to 333.3% with a median increase of 33.1%. Similar changes were observed in each group for free 25OH-D. High FGF23 levels were observed in GB. Conclusions: This study highlighted the differences in VD status and in response to a high dose VD3 in burn patients when compared to healthy patients. Pitfalls in VD status assessment are numerous during acute burn care: 25OH-D measurement needs cautious interpretation and interest of free 25OH-D is still questionable. They should not prevent burn patients to receive VD supplements during acute care. Higher doses than general recommendations should probably be considered. [less ▲]

Detailed reference viewed: 23 (13 ULg)
Full Text
Peer Reviewed
See detailL'éveil de la matrix-gla-protéine sonnera le glas des calcifications vasculaires
DELANAYE, Pierre ULg; Liabeuf, Sophie; BOUQUEGNEAU, Antoine ULg et al

in Néphrologie & Thérapeutique (2015), 11(4), 191-200

La matrix-gla-protéine (MGP) est principalement sécrétée par les chondrocytes et les cellules musculaires lisses des parois vasculaires. Son rôle est d’inhiber localement le développement des ... [more ▼]

La matrix-gla-protéine (MGP) est principalement sécrétée par les chondrocytes et les cellules musculaires lisses des parois vasculaires. Son rôle est d’inhiber localement le développement des calcifications vasculaires. MGP doit bénéficier de deux processus post-transcriptionnels avant d’être pleinement active : une phosphorylation de résidus sérine et une carboxylation de résidus glutamate. Cette carboxylation ne peut se faire qu’en présence de quantité suffisante de vitamine K. Plusieurs formes de MGP circulent donc dans le plasma, certaines étant totalement inactives (la MGP déphosphorylée et décarboxylée), d’autres possédant une activité biologique variable en fonction du nombre de sites carboxylés ou phosphorylés. Il existe un lien théorique étroit entre MGP, vitamine K, calcifications vasculaires et maladies cardiovasculaires et ce, particulièrement chez les patients souffrant d’insuffisance rénale chronique, a fortiori s’ils sont dialysés. Si l’existence de ce lien a été démontrée via de nombreuses et solides données fondamentales, les données cliniques restent, à ce jour, observationnelles et doivent donc être interprétées avec prudence. Mesurer une fraction de MGP dans le plasma pour estimer le degré de calcification d’un patient donné n’est pas encore d’actualité . La forme inactive pourrait être utile pour juger des réserves en vitamine K au niveau vasculaire. Dans cet article de revue, nous reviendrons sur les bases théoriques du rôle de MGP dans le processus de calcification vasculaire, sur le défi analytique que représente sa détermination dans le plasma, ainsi que sur les liens entre MGP, vitamine K et calcifications vasculaires en population géne´ rale et chez les patients insuffisants rénaux. [less ▲]

Detailed reference viewed: 35 (2 ULg)